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Abstract
Background: Mefloquine-artesunate is a formulation of artemisinin based combination therapy (ACT)
recommended by the World Health Organization and historically the first ACT used clinically. The use of ACT
demands constant monitoring of therapeutic efficacies and drug levels, in order to ensure that optimum drug
exposure is achieved and detect reduced susceptibility to these drugs. Quantification of anti-malarial drugs in
biological fluids other than blood would provide a more readily applicable method of therapeutic drug monitoring
in developing endemic countries. Efforts in this study were devoted to the development of a simple, field
applicable, non-invasive method for assay of mefloquine in saliva.
Methods: A high performance liquid chromatographic method with UV detection at 220 nm for assaying
mefloquine in saliva was developed and validated by comparing mefloquine concentrations in saliva and plasma
samples from four healthy volunteers who received single oral dose of mefloquine. Verapamil was used as internal
standard. Chromatographic separation was achieved using a Hypersil ODS column.
Results: Extraction recoveries of mefloquine in plasma or saliva were 76-86% or 83-93% respectively. Limit of
quantification of mefloquine was 20 ng/ml. Agreement between salivary and plasma mefloquine concentrations
was satisfactory (r = 0.88, p < 0.001). Saliva:plasma concentrations ratio was 0.42.
Conclusion: Disposition of mefloquine in saliva paralleled that in plasma, making salivary quantification of
mefloquine potentially useful in therapeutic drug monitoring.
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Background
The morbidity and mortality associated with malaria is
highest in African children with approximately one mil-
lion deaths per year. The spread of drug resistant Plas-
modium falciparum confounds malaria control efforts
and has resulted in the widespread use of artemisinin
based combination therapy (ACT) in the management
of malaria in several sub-Saharan African countries [1].
Mefloquine-artesunate is a formulation of ACT recom-
mended by the World Health Organization [1] and his-
torically the first ACT used clinically. The combination
remains an effective treatment for uncomplicated
malaria [2-5]. The effectiveness of ACT is dependent on
the different modes of action of the drugs in the combi-
nation. The artemisinin derivatives cause an initial rapid
reduction in parasite biomass though they are rapidly
eliminated while the partner drugs such as mefloquine,
lumefantrine, piperaquine, or amodiaquine are more
slowly eliminated and cause subsequent removal of the
remaining parasites. Thus, when combinations of drugs
with discordant half-lives are used, the patient in effect
receives monotherapy with the longer lasting drug
for the tail end of therapy [4]. The overall cure rates,
therefore, depend upon there being sufficient partner
drug to remove the residual parasite biomass left by the
artemisinin derivative. Thus, it is important that the
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macokinetic and pharmacodynamic properties.
Based on this backdrop, the use of ACT demands
constant monitoring of therapeutic efficacies and drug
levels, in order to ensure that optimum drug exposure is
achieved with the dosing strategy and detect reduced
susceptibility to these drugs. Traditionally, anti-malarial
drug levels have been measured in biological fluids such
as whole blood, plasma or red blood cells [2,6-11]
obtained by invasive techniques. This method of sam-
pling poses challenges in resource poor settings and
during epidemiological studies where repeated measure-
ments are required. Thus, quantification of anti-malarial
drugs in biological fluids other than blood would pro-
vide a more readily applicable method of therapeutic
drug monitoring in developing endemic countries. The
use of saliva as an alternative biological fluid in thera-
peutic drug monitoring is justified by the simplicity in
obtaining samples from patients in a non-invasive man-
ner and the possibility of home monitoring. Whole sal-
iva can be collected by individuals with limited training
and no special equipment is required to collect the
fluid, thus saliva represents a potentially useful matrix
for estimating drug levels [12,13]. The major mechanism
by which a drug appears in saliva is thought to be
through passive diffusion across a concentration gradi-
ent and only the unbound fraction of the drug in serum
is available for diffusion into saliva [14]. The unbound
fraction of a drug is usually the pharmacologically active
fraction and this may represent an advantage of drug
monitoring in saliva in comparison with drug monitor-
ing in serum where both bound and unbound drug can
be detected [15].
Methods to measure mefloquine in whole capillary
blood and plasma have been previously described
[16-18], however, these are fraught with limitations. For
instance, sample collection is by invasive techniques in
most cases, some methods require large sample volume,
while others require solid phase extraction. There is no
documented report on estimation of mefloquine concen-
trations in saliva. Thus in this study, efforts were
devoted to the development of a simple, field applicable,
non-invasive method for assay of mefloquine in saliva
and its potential use for therapeutic drug monitoring in
resource poor settings.
Methods
Chemicals
Mefloquine and verapamil (internal standard) were
obtained from Walter Reed Army Research Institute,
USA and their purity was ≥ 99%. All solvents used were
HPLC grade (from Sigma-Aldrich, Milwaukee, USA),
while phosphoric acid and all other reagents employed
were analytical grade (BDH, Polle, UK). Mefloquine
tablets (Mepha Limited, Aesch-Basel, Switzerland) were
purchased locally from a wholesale Pharmacy in Ibadan,
Nigeria.
Instrumentation
The separation of mefloquine was carried out under iso-
cratic condition at room temperature. The HPLC system
consisted of a Cecil 4100 pump, attached to Cecil 4200
variable wavelength UV-Visible detector set at 220 nm.
The chromatograms were recorded and analysed with
PowerStream software (CE 4900) provided with the
instrument (Cecil Instrumen t ,C a m b r i d g e ,U K ) .C h r o -
matographic separation was achieved using a Hypersil
ODS column (4.6 mm × 250 mm; particle size 5 μm).
The mobile phase consisted of phosphate buffer-acetoni-
trile-methanol (40:30:30 v/v/v) with 1% triethylamine
adjusted to a pH 2.8 with concentrated phosphoric acid.
The flow rate of mobile phase was 1.0 ml/min.
Calibration and sample preparation
Stock solutions (1 mg/ml) of mefloquine and verapamil
were prepared in 70% methanol and stored at 4°C.
Working solutions of different concentrations were pre-
pared from the stock. Drug free human plasma or whole
unstimulated saliva (400 μl) was spiked with the working
solution of mefloquine to yield final concentrations of
3,000, 2,000, 1,000, 800, 600, 400, 200 and 0 ng/ml of
mefloquine. The resulting solutions were used to
develop and evaluate the method. The pH of saliva sam-
ples was measured using a pH meter (Mettler,
Switzerland).
Extraction procedure
To plasma or saliva (0.4 ml) in a screw capped 15 ml
polypropylene centrifuge tube, 10 μl (1000 ng) of 100
μg/ml verapamil was added as internal standard. The
mixture was vortexed for 30 seconds. Two milliliters (2
ml) of acetonitrile was added to the mixture followed by
0.5 ml glycine buffer (pH 9.2). The mixture was vor-
t e x e da n dc e n t r i f u g e df o r5m i n u t e s .S u p e r n a t a n tw a s
thereafter removed and transferred into clean tubes.
Two milliliters (2 ml) of dichloromethane was added
and the mixture vortexed for 2 mins and thereafter cen-
trifuged. After centrifugation (1,000 g × 10 min) and
separation, the organic phase was evaporated to dryness
at 37°C under a steady stream of nitrogen. The residue
was reconstituted in 75 μl mobile phase and 40 μlw a s
injected onto the column.
Precision, accuracy and recovery
Sample preparation and extraction were performed on
four replicates at each concentration of mefloquine on
each of four days. Calibration curves were prepared
from the measurement of peak height ratios of the
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reproducibility of the method, coefficients of variation
(CVs) and standard deviations were determined for
intra- and inter-assay variability. Recovery was deter-
mined for each concentration by comparison of peak
height ratio of the extracted known standards with the
directly injected standard concentrations.
Interference
Commonly used anti-malarial drugs including chloro-
quine, pyrimethamine, quinine, amodiaquine, sulphadox-
ine were studied for interference by spiking the drugs in
blank plasma or saliva. The drugs were extracted
according to the method described above. The presence
of peaks was monitored after injection of 40 μlo ft h e
reconstituted sample.
Clinical evaluation
The study protocol was approved by the Joint Ethical
Review Committee of the University of Ibadan/Univer-
sity College Hospital, Ibadan and written informed con-
sent was obtained from each subject prior to inclusion.
All subjects underwent a routine clinical examination
prior to inclusion. Four apparently healthy adult subjects
were enrolled into the study. Subjects had no history of
drug ingestion in the preceding 28 days and each sub-
ject fasted overnight. The demographic data of subjects
such as temperature, weight and age were recorded
before drug administration. Each subject received stan-
dard single oral dose of 20 mg/kg mefloquine base.
Venous blood samples (5 ml) and 1 ml whole unstimu-
l a t e ds a l i v aw e r eo b t a i n e df r o me a c ho ft h ef o u rv o l u n -
teers. Venous blood samples were collected into
heparinised tubes at 0 hr before drug administration,
then at 0.5, 1.0, 2.0, 3.0, 4.0, 6.0, 8.0, 10.0, 12.0, 36.0,
48.0, 72.0, 168, 336, and 504 hr after drug administra-
tion. Saliva samples were collected simultaneously at the
same times as venous blood samples. All subjects rinsed
their mouth with water before producing saliva. The pH
of saliva was determined throughout the sampling per-
iod. Blood was centrifuged (2000 g for 20 min) and the
plasma was removed and stored at -20°C until analysed.
Samples were extracted as described above.
Results
Chromatographs
The calibration curves for mefloquine spiked in drug
free plasma or saliva exhibited good linearity. Linear
regression analysis yielded correlation coefficients r
2 >
0.98 in plasma and r
2 > 0.96 in saliva. The baseline of
mefloquine and the internal standard were well resolved
at the calibration ranges of 0 to 3000 ng/ml with reten-
tion times of 5.0 and 7.0 min for verapamil and meflo-
quine respectively. The separation chromatograms of
mefloquine and the internal standard from spiked
plasma or saliva samples (Figure 1) corresponded with
those of plasma or saliva samples obtained from a
healthy volunteer 6 hr after an oral dose of mefloquine
(Figure 2). All peaks were baseline resolved and clear of
interference from endogenous component of samples.
Recovery, calibration curves and reproducibility
The percentage recovery of mefloquine ranged from 76-
86% and 83-93% in plasma and saliva respectively. The
extraction recoveries for 400 ng/ml, 800 ng/ml and
1,000 ng/ml of mefloquine in plasma or saliva were 75.7
± 6.2% vs 83.3 ± 5.6%, 79.2 ± 4.2% vs 91.3 ± 1.7% and
86.2 ± 2.0% vs 92.8 ± 2.0% (n = 4) respectively. The
intra and inter assay variation of spiked plasma samples
were 1.68% (n = 4) and 7.40% (n = 4) respectively at
200 ng/ml and 4.76% (n = 4) and 2.64% (n = 4) respec-
tively at 1000 ng/ml. The intra- and inter-assay variation
of spiked saliva samples were 1.72% (n = 5) and 4.02%
(n = 5) respectively at 200 ng/ml and 7.00% (n = 4) and
6.62% (n = 4) respectively at 1000 ng/ml. The limit of
quantification of the assay was 20 ng/ml. The limit of
detection of the assay was 6.25 ng/ml as measured by a
peak corresponding to four times the size of baseline
noise at 0.01 absorbance units full-scale (aufs).
Interference
There was no interference from endogenous compounds
or any of the commonly used anti-malarial, analgesic
and anti-infective drugs with the peaks of mefloquine or
the internal standard.
Stability
Comparative short term stability tests were performed
to simulate the effect of different storage and processing
conditions on the stability of mefloquine in saliva versus
plasma. Samples were stored at 37°C, 45°C, room tem-
perature and also made to undergo three freeze-thaw
cycles. The concentrations of mefloquine in these sam-
ples were not affected by different storage or processing
conditions.
Clinical application
Four apparently healthy male subjects were recruited for
this aspect of the study. The mean age and weight of
subjects were 29 years ± 0.4 and 64.5 kg ± 9.9 respec-
tively. Each subject received 20 mg/kg body weight
mefloquine and this was approximately 1,100 mg to
1,480 mg mefloquine base.
The pH of saliva samples collected from healthy subjects
The pH of saliva in the four healthy subjects measured
during the study ranged between 6.4-8.0. The mean pH
of saliva was 7.8 ± 0.1, 7.7 ± 0.3, 7.1 ± 0.3 and 6.8 ± 0.3
Gbotosho et al. Malaria Journal 2012, 11:59
http://www.malariajournal.com/content/11/1/59
Page 3 of 8 
 
 
A
MFQ 
IS 
Time (min) 
B 
Time  (min) 
MFQ 
IS 
Figure 1 Separation of mefloquine (MFQ) and internal standard (IS) from drug free plasma (A) and saliva (B) spiked with 100 μg/ml of
mefloquine.
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Figure 2 Chromatogram of mefloquine (MFQ) and internal standard (IS) in plasma (A) and saliva (B) samples obtained from a
volunteer 6 hrs after a single oral dose of mefloquine (20 mg/kg body weight).
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slightly higher value of the pH of saliva in two subjects
compared with the normal pH of saliva which ranges
between 6.2-7.4.
Pharmacokinetic disposition of Mefloquine in plasma and
saliva
The pharmacokinetic disposition of mefloquine in
plasma and saliva of healthy volunteers is described in
Table 1. There was inter-individual variability in meflo-
quine disposition. Mefloquine was detectable in plasma
and saliva within 30 minutes of oral administration and
reached a maximum concentration within 6-12 hours of
drug administration. The mean time to reach a maxi-
mum concentration in plasma and saliva were similar
(10.0 ± 1.4 hr vs 10.0 ± 1.1 hr, p = 0.999). The mean
maximum concentration of mefloquine in plasma was
almost twice the concentration in saliva (1,016.8 ± 151
ng/ml vs 571.5 ± 77.3 ng/ml, p = 0.066) although the
difference was not statistically significant probably due
to sample size. Following attainment of the peak con-
centration, a decline in mefloquine concentration was
observed and the decline phase of the saliva concentra-
tion time curve were approximately parallel to that in
plasma (Figure 3). The mean saliva concentration of
mefloquine was approximately 2/5 that in plasma.
The mean half-life of mefloquine in plasma and, saliva
were statistically indistinguishable (274 ± 40.4 hr vs
248.8 ± 39.4 hr, p = 0.678). However, there was a statis-
tically significant difference between the mean AUC for
mefloquine in saliva and, plasma. The plasma AUC was
approximately twice the saliva AUC (204191.6 ±
11629.6 ng/ml.h vs 104253.0 ± 7484.1 ng/ml.h, p =
0.001). The oral clearance of mefloquine was signifi-
cantly higher in saliva compared with plasma (p =
0.010). The relationship between instantaneous concen-
tration of mefloquine in saliva and plasma was assessed
by regression analysis and the correlation coefficient was
0.88 (p = 0.0002). The mean saliva/plasma ratio for all
subjects at all time points was 0.42 ± 0.17. Our studies
did not reveal a concentration or time dependent saliva/
plasma ratio (r = 0.2480, p = 0.463 and r = 0.440, p =
0.176 respectively).
Discussion
Therapeutic drug monitoring in saliva offers a painless,
non-invasive and cost effective means of estimating the
free drug concentration in plasma or serum. Unfortu-
nately this biological matrix is infrequently used despite
its potential usefulness. In recent times however, there
has been increased interest in the use of this alternative
matrix for drug treatment testing [12,13,19]. The need
for the use of oral fluid in therapeutic monitoring of
anti-malarial drugs in resource poor malaria endemic
regions cannot be overemphasized. Although, limited
studies have described the pharmacokinetic disposition
of anti-malarial drugs, such as quinine and chloroquine,
in saliva [20,21], this biological matrix is seldom used
for therapeutic drug monitoring. More recently amodia-
quine disposition in saliva was also reported [22], but
no study has described mefloquine determination in
saliva.
The assay described in this paper is a simple and cost
effective method for the analysis of mefloquine in saliva
a n dt h i si st h ef i r s tr e p o r to fm e f l o q u i n ed e t e r m i n a t i o n
in saliva. A two-step extraction procedure was devel-
oped and it was sufficiently sensitive to detect both
mefloquine and the internal standard used (verapamil)
at a wavelength of 220 nm. The extraction solvents gave
optimal recovery of mefloquine and internal standard
from saliva and plasma samples. The advantages of this
assay are that it is relatively inexpensive, sample collec-
tion and processing is rapid and simple and the techni-
que applicable in field settings in resource-poor
countries. Sensitivity and selectivity are also retained
which is necessary for accurate determination of meflo-
quine in saliva.
It is noteworthy that mefloquine was measurable in
saliva within 30 minutes of oral administration such as
has been reported for quinine and amodiaquine [20,22],
a n di tw a sd e t e c t a b l ef o ru pt o5 0 4h o u r sa f t e ras i n g l e
oral dose of 20 mg/kg mefloquine. The concentration of
mefloquine in saliva which represents the free or
unbound fraction was approximately two-fifth that of
plasma. This would suggest that in these healthy volun-
teers mefloquine was probably 60% protein bound. This
value is less than the reported extent of protein binding
of mefloquine (> 98%) [23] and variations in salivary pH
may have accounted for this discrepancy. Passive diffu-
sion across a concentration gradient is thought to be
the major mechanism accounting for the appearance of
a drug in saliva. The pKa of a drug and the pH gradient
Table 1 Comparative pharmacokinetic parameters of
mefloquine in plasma and saliva of healthy adult
volunteers after a single oral dose of mefloquine
Parameters Plasma n = 4 Saliva n = 4 p value
Tmax (h) 10.0 ± 1.4 10.0 ± 1.1 1.000
Range 6.0-12.0 8.0-12.0
Cmax (ng/ml) 1016.8 ± 151.04 571.5 ± 77.0 0.066
Range 675.8-1367.2 437.5-705.4
t1/2 (h) 274.3 ± 40.4.4 248.8 ± 39.4 0.678
Range 175.2-353.1 202.3-327.2
AUC (ng/ml.h) 204191.6 ± 11629.6 104253.0 ± 7848.1 0.001
Range 185448.9-237144.0 95562.3-119918.0
CL (ml/h/kg) 87.2 ± 16.8 171.7 ± 7.3 0.010
Range 53.7-133.9 157.1-181.3
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gradient on both sides of the cell membrane and influ-
ence the availability of a drug in saliva [24]. The pH of
saliva measured during the study was in the range of 6.4
to 8.0 (mean = 7.3 ± 0.25). The presence of a drug in
saliva is influenced by various factors, which include the
physicochemical properties of the drug, lipid solubility,
salivary pH and the degree of protein binding of drug
[25]. These factors may have limited the widespread use
of salivary drug concentrations for therapeutic drug
monitoring. In two of the volunteers, salivary pH range
(7.5-8.0, mean = 7.8 ± 0.1 and 7.0-8.0, mean = 7.7 ±
0.3) was higher than normal saliva pH (6.0-7.4).
Equilibration between saliva and plasma concentra-
tions was rapid and the decline phase of mefloquine in
saliva concentration time-curve was approximately par-
allel to that in plasma in this study. The Cmax and the
AUC0-504 h values obtained from the saliva data were
about half those obtained from plasma while the Tmax
of mefloquine determined from both fluids were similar
and these results were consistent with previous studies
on pharmacokinetics of chloroquine in saliva [21]. The
saliva clearance rate of mefloquine was about twice the
plasma clearance rate such as has also been reported for
chloroquine [21]. The salivary concentration-time profile
reflects the plasma concentration-time profile. The
apparent first order elimination rate constant from sali-
vary concentrations derived from the regression of ln
(salivary concentration) on time was 0.0029 ± 0.0007 h
-1
while the corresponding value derived from plasma was
statistically indistinguishable (0.0027 ± 0.0009 h
-1, p =
0.776). Thus it is possible to derive the apparent first
order elimination rate constant from the salivary
measurements alone. The applicability of the method in
studying pharmacokinetic disposition of mefloquine in
saliva of volunteers suggests that the method may be
suitable in developing disease endemic areas.
A fundamental prerequisite for the application of sal-
iva in therapeutic drug monitoring is a definable rela-
tionship between the concentration of a therapeutic
drug in blood (serum) and the concentration in saliva.
This was established in the present study where a signif-
icant correlation (r = 0.88) was shown to exist between
salivary and plasma mefloquine levels. Similarly, pre-
vious reports of salivary quantification of artemisinin
[26] have shown that concentration of artemisinin in
saliva was comparable to its unbound concentration in
plasma (r = 0.85). The application of saliva for monitor-
ing drug levels has been the subject of considerable
investigation. Several studies have described the useful-
ness of saliva in monitoring patient compliance and
drug levels of psychiatric medications, antiepileptic
drugs, anticancer drugs, and also for the evaluation of
illicit drug use [27-29].
Conclusion
T h ea s s a yd e s c r i b e di nt h i sp a p e ri sas i m p l ea n ds e n s i -
tive method for analysis of mefloquine in saliva, which
appears to enter the saliva passively. The disposition of
mefloquine in saliva appears to be similar to its disposi-
tion in plasma thus measurement of mefloquine in sal-
iva provides a valuable option in therapeutic drug
monitoring. Further pharmacokinetic studies are how-
ever required to evaluate mefloquine concentrations in
saliva during malaria infection in a large population. In
addition, evaluation of the potential to simultaneously
0 100 200 300 400 500 600
0
300
600
900
1200
Time (h)
C
o
n
c
e
n
t
r
a
t
i
o
n
 
(
n
g
/
m
l
)
Figure 3 Concentration - time curve for mefloquine in plasma (▲) and saliva (■) after administration of single oral dose of mefloquine
(20 mg/kg body weight) in healthy volunteers.
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tion therapy with mefloquine is important.
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